drugset / Trial / NCT02380625
Multiple Treatments for Ebola Virus Disease (EVD)
Phase 1/2
Unknown
150 enrolled
Clinical Research Management, Inc.
Bill and Melinda Gates Foundation · collabDuke University · collabSyneos Health · collabUniversity of North Carolina · collabUniversity of Sierra Leone · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether multiple therapeutic regimens are effective in the treatment of Ebola Virus Disease (EVD)
Timeline
- Start
- 2015-04
- Primary completion
- 2016-01
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | 40 mg | — |
| Subject | Azithromycin | Small molecule | 30 mg/kg | Oral |
| Subject | Azithromycin | Small molecule | 500 mg | Oral |
| Subject | Erlotinib | Small molecule | 3 mg/kg | — |
| Subject | Erlotinib | Small molecule | 3.5 mg/kg | — |
| Subject | Erlotinib | Small molecule | 25 mg/kg | — |
| Subject | Erlotinib | Small molecule | 150 mg | — |
| Subject | Irbesartan | Small molecule | 75 mg | — |
| Subject | Irbesartan | Small molecule | 150 mg | — |
| Subject | Sunitinib | Small molecule | 0.83 mg/kg | Oral |
| Subject | Sunitinib | Small molecule | 50 mg | Oral |